Učitavanje...
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma
The combination of clarithromycin, lenalidomide and dexamethasone (BiRd) has led to highly durable responses in newly diagnosed myeloma. However, the ability of clarithromycin to overcome resistance to lenalidomide and dexamethasone (Rd) is not known. To study this, we performed a retrospective anal...
Spremljeno u:
| Izdano u: | Am J Hematol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4390045/ https://ncbi.nlm.nih.gov/pubmed/24723438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23733 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|